Company intelligence / Profile preview

Pantarhei Oncology

Zeist, Netherlands

Ownership: Private
Development stage: Other

Overview

Pantarhei Oncology is a biopharmaceutical company specializing in reproductive endocrine oncology. It focuses on developing innovative treatments for hormone-related cancers, such as breast and prostate cancer, by identifying new medical uses for existing molecules and hormones. Its business model involves developing programs to Proof-of-Concept (Phase 2) before licensing them to larger pharmaceutical partners for Phase 3 and commercialization. Lead programs include the fetal estrogen estetrol (E4) and Zona Pellucida 3 (ZP3) based immunotherapies.

Therapeutic areas: Oncology
Modalities: HormoneSmall moleculeVaccineProtein
Industry: Biotech

Partnerships

Mithra PharmaceuticalsHRA PharmaGedeon Richter

Beyond the preview

Go deeper on Pantarhei Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pantarhei Oncology.

Explore the full profile